Stanford Stem Cell Product, Delayed for More than a Decade, to be Tested Again
By Lisa M. Krieger,
San Jose Mercury News
| 06. 14. 2015
STANFORD -- In the 1990s, Stanford's Irv Weissman created a unique way to grow and deliver blood stem cells to desperate patients with aggressive cancers, boosting survival rates.
But then the discovery itself died -- a victim of the heartbreaking economics of commercial stem-cell development, where the long and rocky road of research, especially in the field of "personalized medicine," often discourages investment.
Now, 10 years after the technique's sale and then abandonment by a biotech company, it is back in Weissman's hands. The goal, he said, is to finally resume his research to prove, once and for all, its effectiveness in patients with no other hope.
"I am frustrated by more than a decade of delay," said Weissman, who codirects the Stanford Institute for Stem Cell Biology and Regenerative Medicine. "But I'm delighted that medical need, rather than rapid profits, is now the primary criterion to translate our stem cell discoveries."
Weissman's discovery was a method to isolate, purify and transplant cells, called blood-forming stem cells. These are the cells deep in the marrow of our bones that generate...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jorge Barrera and Rachel Houlihan, CBC | 04.09.2024
A Canadian DNA laboratory knowingly delivered prenatal paternity test results that routinely identified the wrong biological fathers — ruling out the real dads — and left a trail of shattered lives around the globe, a CBC News investigation has found...